Trichinella spiralis Calreticulin S-Domain Binds to Human Complement C1q to Interfere With C1q-Mediated Immune Functions

Shuai Shao,Chunyue Hao,Bin Zhan,Qinghui Zhuang,Limei Zhao,Yi Chen,Jingjing Huang,Xinping Zhu
DOI: https://doi.org/10.3389/fimmu.2020.572326
IF: 7.3
2020-11-19
Frontiers in Immunology
Abstract:Helminths develop strategies to escape host immune responses that facilitate their survival in the hostile host immune environment. <i>Trichinella spiralis</i>, a tissue-dwelling nematode, has developed a sophisticated strategy to escape complement attack. Our previous study demonstrated that <i>T. spiralis</i> secretes calreticulin (<i>Ts</i>CRT) to inhibit host classical complement activation through binding to C1q; however, the C1q binding site in <i>Ts</i>CRT and the specific mechanism involved with complement-related immune evasion remains unknown. Using molecular docking modeling and fragment expression, we determined that <i>Ts</i>CRT-S, a 153-aa domain of <i>Ts</i>CRT, is responsible for C1q binding. Recombinant <i>Ts</i>CRT-S protein expressed in <i>Escherichia coli</i> had the same capacity to bind and inhibit human C1q-induced complement and neutrophil activation, as full-length <i>Ts</i>CRT. <i>Ts</i>CRT-S inhibited neutrophil reactive oxygen species and elastase release by binding to C1q and reduced neutrophil killing of newborn <i>T. spiralis</i> larvae. Binding of <i>Ts</i>CRT-S to C1q also inhibited formation of neutrophil extracellular traps (NETs), which are involved in autoimmune pathologies and have yet to be therapeutically targeted. These findings provide evidence that the <i>Ts</i>CRT-S fragment, rather than the full-length <i>Ts</i>CRT, is a potential target for vaccine or therapeutic development for trichinellosis, as well as for complement-related autoimmune disease therapies.
immunology
What problem does this paper attempt to address?